Lenvatinib mesylate 是一种口服具有活力的,多靶点酪氨酸激酶抑制剂,能够抑制血管内皮生长因子受体(VEGFR1-3),成纤维细胞生长因子受体(FGFR1-4),干细胞因子受体(KIT),血小板衍生生长因子受体(PDGFR),转染期间重排(RET),具有效抗癌作用。
产品描述
Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
体外活性
Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).?These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors[1].
Cas No.
857890-39-2
分子式
C22H23ClN4O7S
分子量
522.96
别名
仑伐替尼甲酸盐;乐伐替尼;E7080 (mesylate)
储存和溶解度
DMSO:8 mg/mL (15.2 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years